Press Releases

Pancreatic cancer is a terrible disease. The most common form, pancreatic ductal adenocarcinoma (PDAC), has a grim prognosis and the efficacy of existing and experimental treatments leaves much to be desired. Toward addressing the need for new therapies, we are announcing... read post here.

Endometriosis is a painful inflammatory disease that affects millions of women worldwide. The current treatment landscape, which includes over-the-counter pain medication, hormone therapy, and hysterectomy, does not offer sustainable solutions for the vast majority of patients. Therefore, there is a serious unmet clinical need for disease-modifying therapies that provide long-term symptom relief.[1] To that end, we are announcing a collaboration with Adynxx, a clinical-stage biotech, to develop a non-hormonal drug therapy with the potential to address the underlying mechanisms of endometriosis and significantly improve upon the standard of care... read post here.

Our software rapidly provides us and our development partners with lower risk starting points to launch first-in-class therapeutic programs. As mentioned in our Series A post, with SoftBank’s backing we are building a portfolio of self-launched as well as partnered disease programs. The path to an Investigational New Drug (IND) candidate differs for each program and includes a variety of IND-enabling work to optimize the drug candidate. In some cases, the best path to bring a new drug to patients is by developing a prodrug.

Since we met the KemPharm team last year, we have been impressed with their technology and experience. KemPharm’s LAT™ technology was developed to create new prodrugs that are designed to... read post here.

There is a well-established master furniture maker in upstate New York named Jim. I know of Jim because he built the kitchen table in my parents’ house. He builds everything from scratch — kitchen tables, bureaus, custom cabinetry and more — all to exacting specifications. Each one of his pieces is just as much a work of art as it is a piece of functional furniture.
 

A few years ago, I had the opportunity to visit Jim’s workshop and see the environment in which he performs his craft. Located in a barn overlooking a hillside in a rural community... read post here.

Traditionally, building a portfolio of drug programs requires hundreds of millions of dollars and takes many years in the biopharmaceutical industry. The convergence of available biomedical data, affordable cloud computing, and advances in algorithms is now enabling companies to build these drug portfolios for an order of magnitude less money and in a fraction of the time it traditionally takes. This is precisely what twoXAR is doing. Using our artificial intelligence-driven drug discovery platform, we aim to find new, more effective treatments to benefit patients across therapeutic areas.

Today I am proud to share that we have assembled a group of high-quality global investors who will help us achieve this vision. Our Series A, which is led by SoftBank Ventures... read post here

At twoXAR we bring together a lot of disparate data to rapidly identify disease treatments. It’s through these different data that we gain our predictive power. However, more data isn’t always better — not if the new data is of poor quality. In other words, quantity doesn’t trump quality, and that’s because of a common data science saying: bad data in = bad data out. Because of this, we check the quality of our input data at multiple levels; some of this is a manual process, but we automate as much as possible.

In July’s post, (ML)²: Myths and Legends of Machine Learning, I touched on the messiness of real world data and mentioned quality control checks; here, I will expand on that with an example of one of the checks we use for gene expression data... read post here.

Meet twoXAR and other technology-driven life science and healthcare companies for networking, recruiting, and more.

twoXAR Co-Founder, Andrew M. Radin, discusses artificial intelligence in drug discovery.

twoXAR CEO, Andrew A. Radin, discusses artificial intelligence in drug discovery and how it's impacting the discovery of novel ophthalmology therapeutics.

twoXAR CEO, Andrew A. Radin, speaks on AI Applications for Identifying New Drug Candidates panel with Saurabh Saha and Ramesh Durvasula.

twoXAR Co-Founder, Andrew M. Radin, presents Discovering, Validating, & Launching First-In-Class Therapeutic Programs in 4 Months.

twoXAR Co-Founder, Andrew M. Radin, discusses artificial intelligence in drug discovery.

twoXAR CEO, Andrew A. Radin, is joined by GSK's John Baldoni & Nimbus's Mark Ashwell.

twoXAR CEO, Andrew A. Radin, presents What if new medications could be found in minutes instead of years?

twoXAR CEO, Andrew A. Radin, is joined by Jeff Kindler & Vijay Pande.

twoXAR CEO, Andrew A. Radin, speaks with Harry Glorikian of the Moneyball Medicine Podcast.